Financial MarketsWegovyUpdated 3 days ago

FDA Approves First Oral Weight-Loss Medication Wegovy by Novo Nordisk

Novo Nordisk has received FDA approval for Wegovy, the first oral GLP-1 medication for weight loss. This significant milestone allows patients to access a non-injection option for obesity treatment, with availability expected in early 2026. The approval has positively impacted Novo Nordisk's stock, reflecting the market's optimism about this advancement in weight management solutions.

Financial MarketsWegovy

Updated 3 days ago

FDA Approves First Oral Weight-Loss Medication Wegovy by Novo Nordisk

Related Articles (6)

The Wall Street Journal3 days ago

Pill Version of Wegovy Is Approved for Use in the U.S.

PositiveFinancial Markets

Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for the oral version of its weight-loss medication, Wegovy, which is set to be available for purchase at a cash price of $149 per month starting in early 2026. This marks a significant milestone as it is the first GLP-1 medication to be offered in pill form.

Read full article

via The Wall Street Journal

BBC News3 days ago

US regulator approves pill form of Wegovy weight-loss drug

PositiveFinancial Markets

The US regulator has approved Wegovy in pill form, marking a significant shift in the weight-loss drug market by providing a non-injection option for patients. This approval represents a milestone for Novo Nordisk, as Wegovy becomes the first GLP-1 medication available in oral form for weight management.

Read full article

via BBC News

The Guardian3 days ago

US regulators approve Wegovy pill, first oral medication to treat obesity

PositiveFinancial Markets

The U.S. Food and Drug Administration (FDA) has approved Wegovy, the first oral medication for obesity, developed by Novo Nordisk. This approval marks a significant advancement in the treatment of obesity, providing a daily pill option for patients seeking weight loss solutions.

Read full article

via The Guardian

Forbes3 days ago

FDA Approves Pill Version Of Novo Nordisk’s Wegovy—A First For GLP-1s

PositiveFinancial Markets

The FDA has approved the oral version of Novo Nordisk's Wegovy, marking the first time a GLP-1 medication has been made available in pill form for weight management. This approval is a significant milestone for the pharmaceutical company, which has been expanding its portfolio of weight-loss treatments.

Read full article

via Forbes

Investing.com3 days ago

Novo Nordisk wins US approval for weight-loss pill

PositiveFinancial Markets

Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for its oral weight-loss medication, Wegovy, marking a significant advancement in the availability of GLP-1 medications in pill form. This approval is seen as a pivotal moment for the pharmaceutical company, which has been actively expanding its product offerings in the weight management sector.

Read full article

via Investing.com

Investing.com3 days ago

Novo Nordisk stock soars after FDA approves first oral GLP-1 for weight loss

PositiveFinancial Markets

Novo Nordisk's stock surged following the FDA's approval of the first oral GLP-1 medication, Wegovy, for weight loss, marking a significant milestone for the company in the weight management market.

Read full article

via Investing.com